These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 21323890

  • 1. Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age.
    Samuelson S, Sandmaier BM, Heslop HE, Popat U, Carrum G, Champlin RE, Storb R, Prchal JT, Gooley TA, Deeg HJ.
    Br J Haematol; 2011 Apr; 153(1):76-82. PubMed ID: 21323890
    [Abstract] [Full Text] [Related]

  • 2. Allogeneic hematopoietic stem cell transplantation for myelofibrosis.
    Deeg HJ, Gooley TA, Flowers ME, Sale GE, Slattery JT, Anasetti C, Chauncey TR, Doney K, Georges GE, Kiem HP, Martin PJ, Petersdorf EW, Radich J, Sanders JE, Sandmaier BM, Warren EH, Witherspoon RP, Storb R, Appelbaum FR.
    Blood; 2003 Dec 01; 102(12):3912-8. PubMed ID: 12920019
    [Abstract] [Full Text] [Related]

  • 3. Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
    Robin M, Tabrizi R, Mohty M, Furst S, Michallet M, Bay JO, Cahn JY, De Coninck E, Dhedin N, Bernard M, Rio B, Buzyn A, Huynh A, Bilger K, Bordigoni P, Contentin N, Porcher R, Socié G, Milpied N.
    Br J Haematol; 2011 Feb 01; 152(3):331-9. PubMed ID: 21133885
    [Abstract] [Full Text] [Related]

  • 4. Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation.
    Raj K, Eikema DJ, McLornan DP, Olavarria E, Blok HJ, Bregante S, Ciceri F, Passweg J, Ljungman P, Schaap N, Carlson K, Zuckerman T, de Wreede LC, Volin L, Koc Y, Diez-Martin JL, Brossart P, Wolf D, Blaise D, Bartolomeo PD, Vitek A, Robin M, Yakoub-Agha I, Chalandon Y, Kroger N.
    Biol Blood Marrow Transplant; 2019 Mar 01; 25(3):522-528. PubMed ID: 30408564
    [Abstract] [Full Text] [Related]

  • 5. Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis.
    Kröger N, Thiele J, Zander A, Schwerdtfeger R, Kobbe G, Bornhäuser M, Bethge W, Schubert J, de Witte T, Kvasnicka HM, MDS-Subcommittee of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation.
    Exp Hematol; 2007 Nov 01; 35(11):1719-22. PubMed ID: 17976523
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Outcome of transplantation for myelofibrosis.
    Ballen KK, Shrestha S, Sobocinski KA, Zhang MJ, Bashey A, Bolwell BJ, Cervantes F, Devine SM, Gale RP, Gupta V, Hahn TE, Hogan WJ, Kröger N, Litzow MR, Marks DI, Maziarz RT, McCarthy PL, Schiller G, Schouten HC, Roy V, Wiernik PH, Horowitz MM, Giralt SA, Arora M.
    Biol Blood Marrow Transplant; 2010 Mar 01; 16(3):358-67. PubMed ID: 19879949
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group.
    Patriarca F, Masciulli A, Bacigalupo A, Bregante S, Pavoni C, Finazzi MC, Bosi A, Russo D, Narni F, Messina G, Alessandrino EP, Carella AM, Milone G, Bruno B, Mammoliti S, Bruno B, Fanin R, Bonifazi F, Rambaldi A, Gruppo Italiano Trapianti di Midollo Osseo. (GITMO)..
    Biol Blood Marrow Transplant; 2019 May 01; 25(5):932-940. PubMed ID: 30579966
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Splenic irradiation as a component of a reduced-intensity conditioning regimen for hematopoietic stem cell transplantation in myelofibrosis with massive splenomegaly.
    Ito T, Akagi K, Kondo T, Kawabata H, Ichinohe T, Takaori-Kondo A.
    Tohoku J Exp Med; 2012 Dec 01; 228(4):295-9. PubMed ID: 23117264
    [Abstract] [Full Text] [Related]

  • 16. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network.
    Laport GG, Wu J, Logan B, Bachanova V, Hosing C, Fenske T, Longo W, Devine SM, Nademanee A, Gersten I, Horowitz M, Lazarus HM, Riches ML, Blood and Marrow Transplant Clinical Trials Network.
    Biol Blood Marrow Transplant; 2016 Aug 01; 22(8):1440-1448. PubMed ID: 27118571
    [Abstract] [Full Text] [Related]

  • 17. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia.
    Kerbauy DM, Gooley TA, Sale GE, Flowers ME, Doney KC, Georges GE, Greene JE, Linenberger M, Petersdorf E, Sandmaier BM, Scott BL, Sorror M, Stirewalt DL, Stewart FM, Witherspoon RP, Storb R, Appelbaum FR, Deeg HJ.
    Biol Blood Marrow Transplant; 2007 Mar 01; 13(3):355-65. PubMed ID: 17317589
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.